Molecular Templates 
Welcome,         Profile    Billing    Logout  
 7 Products   2 Diseases  7 Products   9 Trials   737 News 
22 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MT-0169 / Molecular Templates
MT-0169-001, NCT04017130: A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma

Terminated
1
14
US
MT-0169
Molecular Templates, Inc.
Relapsed and/or Refractory Multiple Myeloma
12/23
12/23
NCT06522373: Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease

Withdrawn
1
52
NA
MT-0169
M.D. Anderson Cancer Center
Leukemia
10/24
10/24
evofosfamide (IMGS-101) / ImmunoGenesis
EVO, NCT06836726: Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer

Not yet recruiting
2
35
Canada
Evofosfamide
University Health Network, Toronto, ImmunoGenesis
Castration Resistant Prostate Cancer
04/27
04/29
NCT02712567: SARC021C: A Continuation Study of TH-CR-406/SARC021

No Longer Available
N/A
US
Th-302
Sarcoma Alliance for Research through Collaboration, Threshold Pharmaceuticals
Soft Tissue Sarcoma
 
 
MT-3724 / Molecular Templates
2019-001073-86: A study of MT-3724 investigational drug for the treatment of patients with resistant or recurring B-cell cancer

Not yet recruiting
2
108
Europe, RoW
MT-3724, Concentrate for solution for infusion
Molecular Templates, Inc., Molecular Templates, Inc.
relapsed or refractory diffuse large B-cell lymphoma (DLBCL), relapsed or refractory lymphoma, Diseases [C] - Cancer [C04]
 
 
NCT02715843: Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma

No Longer Available
N/A
US
MT-3724
Molecular Templates, Inc.
Non-Hodgkin's B-cell Lymphoma
 
 
Tarlox (tarloxotinib bromide) / Pathos
RAIN, NCT03743350: NSCLC Exon 20 or HER2-activating Mutations

Not yet recruiting
2
40
NA
Tarloxotinib, Tarlox
Rain Therapeutics, inc
Non Small Cell Lung Cancer, EGFR Gene Mutation Exon 20, HER2 Gene Mutation
01/21
01/21
NCT05313009: Tarlox and Sotorasib in Patients With KRAS G12C Mutations

Terminated
1/2
5
US
Sotorasib and Tarloxotinib
Medical University of South Carolina, Rain Oncology Inc
Non-Small Cell Lung Cancer
07/23
12/23
ACTRN12622000369729: Window of opportunity trial of Tarloxotinib combined with stereotactic body radiotherapy (SBRT) in advanced human papilloma virus (HPV) negative head & neck cancer.

Terminated
1
12
 
Te Puriri O Te Ora Directorate of Cancer & Blood at Auckland City Hospital, University of Auckland Li Family Cancer Research Endowment
head and neck cancer
 
 
MT-5111 / Molecular Templates
MT-5111_001, NCT04029922: Study of MT-5111 in HER2-positive Solid Tumors

Terminated
1
50
US, RoW
MT-5111 (experimental study drug)
Molecular Templates, Inc.
HER2-positive Solid Cancers
02/23
04/23
Casgevy (exagamglogene autotemcel) / Vertex, CRISPR Therap, Molecular Templates
2021-006390-37: A study to learn about the safety and efficacy of CTX001 (the "study drug product") to treat beta-thalassemia and severe sickle cell disease in patients

Not yet recruiting
3
18
Europe
Exagamglogene autotemcel (Exa-cel), CTX001, Dispersion for infusion
Vertex Pharmaceuticals Incorporated, VERTEX PHARMACEUTICALS INCORPORATED, Vertex Pharmaceuticals Incorporated,
Transfusion-dependent β-thalassemia (TDT) and severe sickle cell disease (SCD), Transfusion-dependent β-thalassemia and severe sickle cell disease, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
2021-002172-39: A study to learn about the safety and efficacy of CTX001 (the "study drug product") to treat beta-thalassemia in pediatric subjects Studio per comprendere la sicurezza e l'efficacia di CTX001 (il "prodotto in studio") nel trattamento della ß-talassemia in soggetti pediatrici

Not yet recruiting
3
12
Europe
filgrastim, CTX001, Plerixafor, Busulfan, [filgrastim], [CTX001], [Plerixafor], [Busulfan], Solution for injection, Dispersion for infusion, Concentrate for solution for injection/infusion
VERTEX PHARMACEUTICALS INCORPORATED, Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals Incorporated
Transfusion-Dependent ß Thalassemia ß-talassemia trasfusione-dipendente, Transfusion-Dependent ß Thalassemia ß-talassemia trasfusione-dipendente, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
2021-002173-26: A study to learn about the safety and efficacy of CTX001 (the "study drug product") to treat severe sickle cell disease in a pediatric subjects Uno studio per conoscere la sicurezza e l'efficacia di CTX001 (il "prodotto in studio") per il trattamento della malattia a cellule falciformi grave in soggetti pediatrici

Not yet recruiting
3
12
Europe
CTX001, Plerixafor, Busulfan, [CTX001], [Plerixafor], [Busulfan], Dispersion for infusion, Solution for injection, Concentrate for solution for injection/infusion
VERTEX PHARMACEUTICALS INCORPORATED, Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals Incorporated
Severe Sickle Cell Disease (SCD) Malattia a cellule falciformi grave, Severe Sickle Cell Disease Malattia a cellule falciformi grave, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
NCT05477563 / 2021-006390-37: Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

Recruiting
3
26
Europe, US, RoW
CTX001, Exagamglogene autotemcel, Exa-cel
Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics
Beta-Thalassemia, Thalassemia, Hematologic Diseases, Genetic Diseases, Inborn, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Anemia
06/27
06/27
NCT05329649 / 2021-002173-26: Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)

Recruiting
3
15
Europe, US
CTX001, Exagamglogene autotemcel, Exa-cel
Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics
Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance, Hemoglobinopathies, Hematological Diseases
05/26
05/26
NCT05356195 / 2021-002172-39: Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

Recruiting
3
15
Europe, Canada, US
CTX001, Exagamglogene autotemcel, Exa-cel
Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics
Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies
05/26
05/26
NCT05951205: Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/βC Genotype

Not yet recruiting
3
12
NA
Exa-cel, Exagamglogene autotemcel, CTX001
Vertex Pharmaceuticals Incorporated
Sickle Cell Disease
12/33
12/33
CTX001-131, NCT04208529 / 2018-002935-88: A Long-term Follow-up Study in Participants Who Received CTX001

Enrolling by invitation
3
160
Europe, Canada, US
CTX001, Exagamglogene autotemcel, Exa-cel
Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics
Beta-Thalassemia, Thalassemia, Sickle Cell Disease, Hematologic Diseases, Hemoglobinopathies, Genetic Diseases, Inborn, Sickle Cell Anemia
09/39
09/39
CLIMB THAL-111, NCT03655678 / 2017-003351-38: A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia

Active, not recruiting
2/3
59
Europe, Canada, US
CTX001, Exagamglogene autotemcel, Exa-cel
Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics
Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies
12/25
12/25
CLIMB SCD-121, NCT03745287 / 2018-001320-19: A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease

Active, not recruiting
2/3
63
Europe, Canada, US
CTX001, Exagamglogene autotemcel, Exa-cel
Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics
Sickle Cell Disease, Hematological Diseases, Hemoglobinopathies
07/25
07/25
MT-6402 / Molecular Templates
MT-6402-001, NCT04795713: Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Terminated
1
64
US
MT-6402
Molecular Templates, Inc.
Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
10/24
10/24
MT-8421 / Molecular Templates
MT-8421-001, NCT06034860: Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

Terminated
1
15
US
MT-8421, Nivolumab
Molecular Templates, Inc.
Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma, Renal Cell Carcinoma, Microsatellite Instability High, Mismatch Repair Deficiency, Mesothelioma, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Cervical Cancer
10/24
10/24
Undisclosed Trop2-targeted ETB / Molecular Templates
No trials found
Undisclosed CD117 targeting ETB / Molecular Templates
No trials found
SLAMF-7 ETB / Molecular Templates
No trials found
Undisclosed TIGIT ETB / Molecular Templates
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MT-0169 / Molecular Templates
MT-0169-001, NCT04017130: A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma

Terminated
1
14
US
MT-0169
Molecular Templates, Inc.
Relapsed and/or Refractory Multiple Myeloma
12/23
12/23
NCT06522373: Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease

Withdrawn
1
52
NA
MT-0169
M.D. Anderson Cancer Center
Leukemia
10/24
10/24
evofosfamide (IMGS-101) / ImmunoGenesis
EVO, NCT06836726: Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer

Not yet recruiting
2
35
Canada
Evofosfamide
University Health Network, Toronto, ImmunoGenesis
Castration Resistant Prostate Cancer
04/27
04/29
NCT02712567: SARC021C: A Continuation Study of TH-CR-406/SARC021

No Longer Available
N/A
US
Th-302
Sarcoma Alliance for Research through Collaboration, Threshold Pharmaceuticals
Soft Tissue Sarcoma
 
 
MT-3724 / Molecular Templates
2019-001073-86: A study of MT-3724 investigational drug for the treatment of patients with resistant or recurring B-cell cancer

Not yet recruiting
2
108
Europe, RoW
MT-3724, Concentrate for solution for infusion
Molecular Templates, Inc., Molecular Templates, Inc.
relapsed or refractory diffuse large B-cell lymphoma (DLBCL), relapsed or refractory lymphoma, Diseases [C] - Cancer [C04]
 
 
NCT02715843: Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma

No Longer Available
N/A
US
MT-3724
Molecular Templates, Inc.
Non-Hodgkin's B-cell Lymphoma
 
 
Tarlox (tarloxotinib bromide) / Pathos
RAIN, NCT03743350: NSCLC Exon 20 or HER2-activating Mutations

Not yet recruiting
2
40
NA
Tarloxotinib, Tarlox
Rain Therapeutics, inc
Non Small Cell Lung Cancer, EGFR Gene Mutation Exon 20, HER2 Gene Mutation
01/21
01/21
NCT05313009: Tarlox and Sotorasib in Patients With KRAS G12C Mutations

Terminated
1/2
5
US
Sotorasib and Tarloxotinib
Medical University of South Carolina, Rain Oncology Inc
Non-Small Cell Lung Cancer
07/23
12/23
ACTRN12622000369729: Window of opportunity trial of Tarloxotinib combined with stereotactic body radiotherapy (SBRT) in advanced human papilloma virus (HPV) negative head & neck cancer.

Terminated
1
12
 
Te Puriri O Te Ora Directorate of Cancer & Blood at Auckland City Hospital, University of Auckland Li Family Cancer Research Endowment
head and neck cancer
 
 
MT-5111 / Molecular Templates
MT-5111_001, NCT04029922: Study of MT-5111 in HER2-positive Solid Tumors

Terminated
1
50
US, RoW
MT-5111 (experimental study drug)
Molecular Templates, Inc.
HER2-positive Solid Cancers
02/23
04/23
Casgevy (exagamglogene autotemcel) / Vertex, CRISPR Therap, Molecular Templates
2021-006390-37: A study to learn about the safety and efficacy of CTX001 (the "study drug product") to treat beta-thalassemia and severe sickle cell disease in patients

Not yet recruiting
3
18
Europe
Exagamglogene autotemcel (Exa-cel), CTX001, Dispersion for infusion
Vertex Pharmaceuticals Incorporated, VERTEX PHARMACEUTICALS INCORPORATED, Vertex Pharmaceuticals Incorporated,
Transfusion-dependent β-thalassemia (TDT) and severe sickle cell disease (SCD), Transfusion-dependent β-thalassemia and severe sickle cell disease, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
2021-002172-39: A study to learn about the safety and efficacy of CTX001 (the "study drug product") to treat beta-thalassemia in pediatric subjects Studio per comprendere la sicurezza e l'efficacia di CTX001 (il "prodotto in studio") nel trattamento della ß-talassemia in soggetti pediatrici

Not yet recruiting
3
12
Europe
filgrastim, CTX001, Plerixafor, Busulfan, [filgrastim], [CTX001], [Plerixafor], [Busulfan], Solution for injection, Dispersion for infusion, Concentrate for solution for injection/infusion
VERTEX PHARMACEUTICALS INCORPORATED, Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals Incorporated
Transfusion-Dependent ß Thalassemia ß-talassemia trasfusione-dipendente, Transfusion-Dependent ß Thalassemia ß-talassemia trasfusione-dipendente, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
2021-002173-26: A study to learn about the safety and efficacy of CTX001 (the "study drug product") to treat severe sickle cell disease in a pediatric subjects Uno studio per conoscere la sicurezza e l'efficacia di CTX001 (il "prodotto in studio") per il trattamento della malattia a cellule falciformi grave in soggetti pediatrici

Not yet recruiting
3
12
Europe
CTX001, Plerixafor, Busulfan, [CTX001], [Plerixafor], [Busulfan], Dispersion for infusion, Solution for injection, Concentrate for solution for injection/infusion
VERTEX PHARMACEUTICALS INCORPORATED, Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals Incorporated
Severe Sickle Cell Disease (SCD) Malattia a cellule falciformi grave, Severe Sickle Cell Disease Malattia a cellule falciformi grave, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
NCT05477563 / 2021-006390-37: Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

Recruiting
3
26
Europe, US, RoW
CTX001, Exagamglogene autotemcel, Exa-cel
Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics
Beta-Thalassemia, Thalassemia, Hematologic Diseases, Genetic Diseases, Inborn, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Anemia
06/27
06/27
NCT05329649 / 2021-002173-26: Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)

Recruiting
3
15
Europe, US
CTX001, Exagamglogene autotemcel, Exa-cel
Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics
Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance, Hemoglobinopathies, Hematological Diseases
05/26
05/26
NCT05356195 / 2021-002172-39: Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

Recruiting
3
15
Europe, Canada, US
CTX001, Exagamglogene autotemcel, Exa-cel
Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics
Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies
05/26
05/26
NCT05951205: Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/βC Genotype

Not yet recruiting
3
12
NA
Exa-cel, Exagamglogene autotemcel, CTX001
Vertex Pharmaceuticals Incorporated
Sickle Cell Disease
12/33
12/33
CTX001-131, NCT04208529 / 2018-002935-88: A Long-term Follow-up Study in Participants Who Received CTX001

Enrolling by invitation
3
160
Europe, Canada, US
CTX001, Exagamglogene autotemcel, Exa-cel
Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics
Beta-Thalassemia, Thalassemia, Sickle Cell Disease, Hematologic Diseases, Hemoglobinopathies, Genetic Diseases, Inborn, Sickle Cell Anemia
09/39
09/39
CLIMB THAL-111, NCT03655678 / 2017-003351-38: A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia

Active, not recruiting
2/3
59
Europe, Canada, US
CTX001, Exagamglogene autotemcel, Exa-cel
Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics
Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies
12/25
12/25
CLIMB SCD-121, NCT03745287 / 2018-001320-19: A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease

Active, not recruiting
2/3
63
Europe, Canada, US
CTX001, Exagamglogene autotemcel, Exa-cel
Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics
Sickle Cell Disease, Hematological Diseases, Hemoglobinopathies
07/25
07/25
MT-6402 / Molecular Templates
MT-6402-001, NCT04795713: Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Terminated
1
64
US
MT-6402
Molecular Templates, Inc.
Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
10/24
10/24
MT-8421 / Molecular Templates
MT-8421-001, NCT06034860: Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

Terminated
1
15
US
MT-8421, Nivolumab
Molecular Templates, Inc.
Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma, Renal Cell Carcinoma, Microsatellite Instability High, Mismatch Repair Deficiency, Mesothelioma, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Cervical Cancer
10/24
10/24
Undisclosed Trop2-targeted ETB / Molecular Templates
No trials found
Undisclosed CD117 targeting ETB / Molecular Templates
No trials found
SLAMF-7 ETB / Molecular Templates
No trials found
Undisclosed TIGIT ETB / Molecular Templates
No trials found

Download Options